Generated by AI
Cadrenal Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing therapies for life-threatening immune and thrombotic conditions. Its lead program centers on CAD-1005, a first-in-class 12-LOX inhibitor being studied for heparin-induced thrombocytopenia, a serious immune-mediated clotting disorder. The company’s pipeline also includes tecarfarin, an oral vitamin K antagonist designed for patients with chronic anticoagulation needs, including those with end-stage kidney disease and left ventricular assist devices, as well as frunexian, a parenteral Factor XIa inhibitor being developed for acute hospital use. Cadrenal Therapeutics Inc. serves the specialized cardiovascular and hematology markets, where it aims to address unmet needs in anticoagulation and thrombosis management through targeted, clinically differentiated drug candidates.
Website822 A1A North
Ponte Vedra, FL, 32082
United States
The latest articles about CVKD.
PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in the 28th Annual H.C. Wainwright Global Investment Conference, September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded presentation from the Company will be available on demand
Summary of Nov 17's posts. Generated by AI.
Summary of Feb 28's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about CVKD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.